Literature DB >> 19844736

Ocular surface inflammation, and nerve growth factor level in tears in active thyroid-associated ophthalmopathy.

Jin Sook Yoon1, Soo Hyun Choi, Joon H Lee, Sung Jun Lee, Sang Yeul Lee.   

Abstract

PURPOSE: To measure tear nerve growth factor (NGF) concentrations in cases of active thyroid-associated ophthalmopathy (TAO) before and after glucocorticoid treatment, and to correlate NGF levels with disease inflammatory activity and thyroid autoantibody concentration.
METHODS: The study involved 20 patients with active TAO and 20 age- and gender-matched controls. Tear break-up time (BUT) was obtained, the Schirmer test was performed, and tear NGF/total protein ratio was measured in control subjects and patients with active TAO before, and 2 and 4 weeks after, steroid treatment.
RESULTS: Tear BUT and Schirmer values significantly increased after 2 and 4 weeks of steroid treatment (p < 0.001 and p = 0.004 respectively). Baseline tear NGF/total protein ratio was higher in patients with active TAO than in control subjects, and the ratio significantly decreased after 2 and 4 weeks of steroid treatment (p < 0.001). Tear NGF/total protein ratio did not correlate with inflammatory activity score, exophthalmos value and thyroid binding inhibiting immunoglobulin (TBII) level (p > 0.05).
CONCLUSIONS: Tear NGF may have a specific role in ocular surface inflammation, which protects against ocular surface damage in patients with active TAO. Anti-inflammatory treatment significantly reduced the level of NGF in tears, increased tear film stability and production, and decreased congestive symptoms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19844736     DOI: 10.1007/s00417-009-1215-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  24 in total

1.  Correlation of orbital computed tomography and antibodies in patients with hyperthyroid Graves' disease.

Authors:  T C Chang; K M Huang; T J Chang; S L Lin
Journal:  Clin Endocrinol (Oxf)       Date:  1990-05       Impact factor: 3.478

2.  Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy.

Authors:  M P Mourits; M F Prummel; W M Wiersinga; L Koornneef
Journal:  Clin Endocrinol (Oxf)       Date:  1997-07       Impact factor: 3.478

3.  Analysis of tear proteins in Graves' ophthalmopathy by high performance liquid chromatography.

Authors:  H A Khalil; R J de Keizer; A Kijlstra
Journal:  Am J Ophthalmol       Date:  1988-08-15       Impact factor: 5.258

Review 4.  Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment.

Authors:  D H Jacobson; C A Gorman
Journal:  Endocr Rev       Date:  1984       Impact factor: 19.871

5.  Ocular surface drying and tear film osmolarity in thyroid eye disease.

Authors:  J P Gilbard; R L Farris
Journal:  Acta Ophthalmol (Copenh)       Date:  1983-02

6.  Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide.

Authors:  R Moncayo; I Baldissera; C Decristoforo; D Kendler; E Donnemiller
Journal:  Thyroid       Date:  1997-02       Impact factor: 6.568

7.  Expression of nerve growth factor receptors on the ocular surface in healthy subjects and during manifestation of inflammatory diseases.

Authors:  A Lambiase; S Bonini; A Micera; P Rama; S Bonini; L Aloe
Journal:  Invest Ophthalmol Vis Sci       Date:  1998-06       Impact factor: 4.799

Review 8.  Nerve growth factor and the immune system: old and new concepts in the cross-talk between immune and resident cells during pathophysiological conditions.

Authors:  Alessandro Lambiase; Alessandra Micera; Roberto Sgrulletta; Sergio Bonini; Stefano Bonini
Journal:  Curr Opin Allergy Clin Immunol       Date:  2004-10

Review 9.  New insights on the involvement of Nerve Growth Factor in allergic inflammation and fibrosis.

Authors:  Alessandra Micera; Ilaria Puxeddu; Luigi Aloe; Francesca Levi-Schaffer
Journal:  Cytokine Growth Factor Rev       Date:  2003-10       Impact factor: 7.638

10.  Correlation of CT scanning and pathologic features of ophthalmic Graves' disease.

Authors:  S L Trokel; F A Jakobiec
Journal:  Ophthalmology       Date:  1981-06       Impact factor: 12.079

View more
  5 in total

1.  Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy.

Authors:  Danping Huang; Nuo Xu; Yiyue Song; Peijuan Wang; Huasheng Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-30       Impact factor: 3.117

2.  The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis.

Authors:  Jelena Juri Mandić; Ana Kozmar; Sanja Kusačić-Kuna; Anamarija Jazbec; Krešimir Mandić; Danijela Mrazovac; Nenad Vukojević
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-01-14       Impact factor: 3.117

3.  Elevated percentage of HLA-DR⁺ and ICAM-1⁺ conjunctival epithelial cells in active Graves' orbitopathy.

Authors:  P Pawlowski; J Mysliwiec; M Mrugacz; J Zak; A Bakunowicz-Lazarczyk; R Rejdak; J Wysocka; M Gorska
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-23       Impact factor: 3.117

4.  In vivo confocal microscopy assessment of meibomian glands microstructure in patients with Graves' orbitopathy.

Authors:  Shengnan Cheng; Yueqi Yu; Jin Chen; Lin Ye; Xinghua Wang; Fagang Jiang
Journal:  BMC Ophthalmol       Date:  2021-06-19       Impact factor: 2.209

5.  Patient acceptability of tear collection in the primary healthcare setting.

Authors:  Joanne Hui Min Quah; Louis Tong; Sylvaine Barbier
Journal:  Optom Vis Sci       Date:  2014-04       Impact factor: 1.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.